Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking less necessary.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel reality.
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
The offer would put an 83% premium on Soho’s Wednesday closing price and comes a year after it had to close off admissions in three cities.
One ring to rule them all… at least, Oura hopes so. On Thursday, it announced a new $200 million funding round.
Will a shutdown happen? Maybe not. But what if it does? What would a holiday season shutdown actually mean?